Evidence map›Paper›PMID 19730134›Full record

ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2009

Leptin deficiency: clinical implications and opportunities for therapeutic interventions.

Susan Blüher, Sunali Shah, Christos S Mantzoros

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Gut microbiota in overweight and obesity: crosstalk with adipose tissue.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Leptin applications in 2015: what have we learned about leptin and obesity?Current opinion in endocrinology, diabetes, and obesity · 2015
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Leptin and mucosal immunity.Mucosal immunology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Susan BlüherHospital for Children and Adolescents, University of Leipzig, Germany.
Sunali Shah
Christos S Mantzoros
Beth Israel Deaconess Medical Center · US

Funding

AFMR-Translational Medical Research Symposia SeriesR13RR023236 · NCRR · AMERICAN FEDERATION FOR MEDICAL RESEARCH · PI ZUCKER, DEBORAH R · 2006 to 2010
$263k
NCRR NIH HHS R13 RR023236Wellcome Trust
6 · The paper itself

Abstract

The discovery of leptin has significantly advanced our understanding of the metabolic importance of adipose tissue and has revealed that both leptin deficiency and leptin excess are associated with severe metabolic, endocrine, and immunological consequences. We and others have shown that a prominent role of leptin in humans is to mediate the neuroendocrine adaptation to energy deprivation. Humans with genetic mutations in the leptin and leptin receptor genes have deregulated food intake and energy expenditure leading to a morbidly obese phenotype and a disrupted regulation in neuroendocrine and immune function and in glucose and fat metabolism. Observational and interventional studies in humans with (complete) congenital leptin deficiency caused by mutations in the leptin gene or with relative leptin deficiency as seen in states of negative energy balance such as lipoatrophy, anorexia nervosa, or exercise-induced hypothalamic and neuroendocrine dysfunction have contributed to the elucidation of the pathophysiological role of leptin in these conditions and of the clinical significance of leptin administration in these subjects. More specifically, interventional studies have demonstrated that several neuroendocrine, metabolic, or immune disturbances in these states could be restored by leptin administration. Leptin replacement therapy is currently available through a compassionate use program for congenital complete leptin deficiency and under an expanded access program to subjects with leptin deficiency associated with congenital or acquired lipoatrophy. In addition, leptin remains a potentially forthcoming treatment for several other states of energy deprivation including anorexia nervosa or milder forms of hypothalamic amenorrhea pending appropriate clinical trials.

Indexed as

Adrenal GlandsAmenorrheaAnorexia NervosaCognitionFemaleHumansHypothalamo-Hypophyseal SystemLeptinLipodystrophyMaleModels, BiologicalNeurosecretory SystemsReproductionThyroid GlandLeptin

Identifiers

PMID19730134
PMCPMC5501320
OpenAlexW301048312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.